General Information:

Id: 1,090
Diseases: Amyotrophic lateral sclerosis
Homo sapiens
Reference: Fornai F et al.(2008) Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 105: 2052-2057 [PMID: 18250315]

Interaction Information:

Comment In a study, the authors found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter, delay disease progression in human patients affected by ALS. None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time.
Formal Description
Interaction-ID: 6903

drug/chemical compound


decreases_activity of


Amyotrophic lateral sclerosis

Drugbank entries Show/Hide entries for Lithium